Source: Annual Congress 2001 - New developments in inhaled corticosteroid therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. S. Bundschuh, D. Marx, A. Hatzelmann, R. Beume, D. Haefner, G. Hochhaus, F. Montoro, R. Riedel, M. Stoeck (Konstanz, Germany; Gainesville, United States Of America; Madrid, Spain). Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide. Eur Respir J 2001; 16: Suppl. 31, 1013

Member's Comments

No comment yet.

Related content which might interest you: In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001 Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001 Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001 Indacaterol: preclinical evidence for an improved safety profile vs LABAs Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005 Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002 Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011 The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010